MetaCap

MoonLake Immunotherapeutics Insider Trades

NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.82+0.24 (+2.27%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
27 · $83.03M
Shares bought / sold
0 / 4.88M
Net activity
Net selling $83.0 million

MoonLake Immunotherapeutics insider activity

Over the last 12 months, MoonLake Immunotherapeutics insiders reported 34 transactions on SEC Form 4: 0 open-market purchases and 27 sales. Insiders bought $0 and sold $83.0 million worth of stock, for net insider selling of $83.0 million. The largest seller was BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK N, with $63.0 million in reported sales.

The most recent filing shows Reich Kristian (Chief Scientific Officer) selling 1,100 shares at $20.00 on Jul 27, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put MLTX's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

MLTX insider transactions

MoonLake Immunotherapeutics insider transactions
DateInsiderTypeSharesValueFiling
Jul 27, 2026Reich KristianChief Scientific OfficerSale1,100$22.00KForm 4
Jul 22, 2026Reich KristianChief Scientific OfficerSale2,448$48.96KForm 4
Jul 21, 2026Reich KristianChief Scientific OfficerSale50,000$1.00MForm 4
Jul 20, 2026Reich KristianChief Scientific OfficerSale43,700$877.93KForm 4
Jul 15, 2026Reich KristianChief Scientific OfficerSale16,105$322.26KForm 4
Jul 10, 2026Santos da Silva JorgeChief Executive OfficerSale68,289$1.37MForm 4
Jul 9, 2026Santos da Silva JorgeChief Executive OfficerSale33,936$679.06KForm 4
Jul 1, 2026Santos da Silva JorgeChief Executive OfficerSale47,775$956.93KForm 4
Jun 22, 2026Bodenstedt MatthiasChief Financial OfficerSale39,120$862.20KForm 4
Jun 18, 2026Bodenstedt MatthiasChief Financial OfficerSale2,794$54.76KForm 4
Jun 17, 2026Reich KristianChief Scientific OfficerSale50,000$971.50KForm 4
Jun 17, 2026Bodenstedt MatthiasChief Financial OfficerSale15,082$296.81KForm 4
Jun 16, 2026Reich KristianChief Scientific OfficerSale50,000$935.00KForm 4
Jun 15, 2026Reich KristianChief Scientific OfficerSale50,000$944.50KForm 4
May 11, 2026Bodenstedt MatthiasChief Financial OfficerSale13,653$273.33KForm 4
Apr 14, 2026Bodenstedt MatthiasChief Financial OfficerSale2,426$47.45KForm 4
Apr 13, 2026Santos da Silva JorgeChief Executive OfficerSale51,873$945.64KForm 4
Apr 10, 2026Bodenstedt MatthiasChief Financial OfficerSale1,925$37.56KForm 4
Apr 10, 2026Santos da Silva JorgeChief Executive OfficerSale98,127$1.81MForm 4
Apr 9, 2026Bodenstedt MatthiasChief Financial OfficerSale85,870$1.63MForm 4
Mar 31, 2026BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK NDirectorSale248,530$4.17MForm 4
Mar 31, 2026BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK NDirectorSale1,569,116$26.35MForm 4
Mar 31, 2026BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK NDirectorSale1,932,354$32.44MForm 4
Jan 7, 2026Bodenstedt MatthiasChief Financial OfficerAward354,296—Form 4
Dec 19, 2025Santos da Silva JorgeChief Executive OfficerDisposition196,316—Form 4
Dec 19, 2025Santos da Silva JorgeChief Executive OfficerConversion196,316—Form 4
Dec 19, 2025Reich KristianChief Scientific OfficerDisposition35,389—Form 4
Dec 19, 2025Reich KristianChief Scientific OfficerConversion35,389—Form 4
Dec 19, 2025Bodenstedt MatthiasChief Financial OfficerDisposition294,473—Form 4
Dec 19, 2025Bodenstedt MatthiasChief Financial OfficerConversion294,473—Form 4
Dec 9, 2025Reich KristianChief Scientific OfficerSale72,908$1.05MForm 4
Dec 9, 2025Santos da Silva JorgeChief Executive OfficerSale70,000$1.01MForm 4
Dec 8, 2025Reich KristianChief Scientific OfficerSale130,000$1.96MForm 4
Dec 8, 2025Santos da Silva JorgeChief Executive OfficerSale130,000$1.96MForm 4
Oct 8, 2025Bodenstedt MatthiasChief Financial OfficerBuy10,870$98.81KForm 4
Sep 30, 2025Chen Bihua & Cormorant Asset Management, LP & Cormorant Global Healthcare Master Fund, LP & Cormorant Private Healthcare Fund II, LP & Cormorant Private Healthcare Fund III LP & Cormorant Private Healthcare Fund IV LPFormer 10% OwnerSale5,827$40.56KForm 4
Sep 29, 2025Chen Bihua & Cormorant Asset Management, LP & Cormorant Global Healthcare Master Fund, LP & Cormorant Private Healthcare Fund II, LP & Cormorant Private Healthcare Fund III LP & Cormorant Private Healthcare Fund IV LPFormer 10% OwnerSale2,800,000$18.51MForm 4
Sep 29, 2025Chen Bihua & Cormorant Asset Management, LP & Cormorant Global Healthcare Master Fund, LP & Cormorant Private Healthcare Fund II, LP & Cormorant Private Healthcare Fund III LP & Cormorant Private Healthcare Fund IV LPFormer 10% OwnerSale3,390,943$25.70MForm 4
Sep 29, 2025Chen Bihua & Cormorant Asset Management, LP & Cormorant Global Healthcare Master Fund, LP & Cormorant Private Healthcare Fund II, LP & Cormorant Private Healthcare Fund III LP & Cormorant Private Healthcare Fund IV LPFormer 10% OwnerSale232,460$1.95MForm 4
Sep 29, 2025Chen Bihua & Cormorant Asset Management, LP & Cormorant Global Healthcare Master Fund, LP & Cormorant Private Healthcare Fund II, LP & Cormorant Private Healthcare Fund III LP & Cormorant Private Healthcare Fund IV LPFormer 10% OwnerSale70,748$663.62KForm 4
Sep 2, 2025Reich KristianChief Scientific OfficerDisposition48,978—Form 4
Sep 2, 2025Reich KristianChief Scientific OfficerConversion48,978—Form 4
Jul 3, 2025Moukheibir CatherineDirectorSale23,500$1.15MForm 4
Jul 3, 2025Moukheibir CatherineDirectorOption exercise23,500—Form 4
Feb 27, 2025Bodenstedt MatthiasChief Financial OfficerAward95,763—Form 4
Feb 27, 2025Santos da Silva JorgeChief Executive OfficerAward95,763—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related